Fountain Healthcare Partners

Neuromod Devices Limited is a Dublin-based medical device company founded in 2010, focusing on the research and development of neuromodulation treatments for chronic tinnitus, a condition affecting approximately 10% of adults. The company has developed a patented bi-modal neuromodulation technology, exemplified by its product, the mutebutton. This device aims to promote positive therapeutic changes in the nervous system, offering a targeted approach to alleviate the suffering of patients living with chronic tinnitus. Neuromod is dedicated to providing innovative treatments that empower patients to manage their conditions while integrating seamlessly into their modern lifestyles.

Mainstay Medical is a global medical device company based in Dublin, Ireland, with operations in the United States and Australia. The company focuses on developing innovative therapies for individuals suffering from chronic low back pain, a condition that affects a significant portion of the population. Mainstay Medical has created a FDA-approved restorative treatment aimed at addressing mechanical chronic low back pain. This treatment is designed to help restore muscle control and enhance functionality in the lumbar spine, ultimately improving the quality of life for patients. By collaborating with scientists and clinical experts, Mainstay Medical strives to provide effective solutions for those in need of relief from debilitating pain.

We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The Symani® Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients.

Corteria Pharmaceuticals develops first-in-class drugs in heart failure subpopulations, focused on the development of transformative therapies for the treatment of worsening and acute decompensated heart failure.

Neuromod Devices Limited is a Dublin-based medical device company founded in 2010, focusing on the research and development of neuromodulation treatments for chronic tinnitus, a condition affecting approximately 10% of adults. The company has developed a patented bi-modal neuromodulation technology, exemplified by its product, the mutebutton. This device aims to promote positive therapeutic changes in the nervous system, offering a targeted approach to alleviate the suffering of patients living with chronic tinnitus. Neuromod is dedicated to providing innovative treatments that empower patients to manage their conditions while integrating seamlessly into their modern lifestyles.

We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The Symani® Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients.

Ermium Therapeutics is a biotechnology company based in Paris, France, focused on developing innovative therapies for autoimmune and inflammatory diseases. Founded in June 2019, the company is centered around a breakthrough discovery that identifies CXCR4 as a master regulator of inflammation. This research underpins the development of therapies that aim to control interferons through plasmacytoid dendritic cells. Ermium Therapeutics has secured a worldwide exclusive license for its intellectual property from CNRS and the University of Paris Descartes, facilitated by an agreement with Erganeo, which has supported the project's academic maturation. The company has gained recognition for its work, notably receiving the innovation i-Lab 2019 award from the French Ministry of Research and Higher Education.

Vivasure Medical Limited is a medical device company based in Galway, Ireland, specializing in the research, development, and manufacture of arterial and venous closure devices utilizing its patented PerQseal technology. The company focuses on creating polymer implants and delivery systems aimed at minimally invasive vessel closures in the fields of cardiology, interventional radiology, and vascular surgery. Its primary product is a large-bore percutaneous closure device that employs an absorbable patch to effectively close large arteriotomies following transcatheter procedures, including transcatheter aortic valve replacement and endovascular aneurysm repair. Established in 2008, Vivasure Medical is dedicated to advancing medical solutions that enhance patient outcomes in vascular access procedures.

Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck Serono, a global leader in auto-immune diseases and biologics. Calypso Biotech was initially financed through a 2.5 million euro seed-fund managed by MS Ventures.A highly experienced management team with strong expertise in drug development and an extensive scientific and industry network manages Calypso Biotech. They operate as a nimble, semi-virtual organization in order to create substantial added value for their investors from a portfolio of unique proprietary antibody candidates.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, specializing in the development of neurokinin (NK) receptor antagonists for clinical and preclinical use. Founded in 2012, the company focuses on creating innovative therapies to address conditions related to neuronal hypersensitivity. Its lead asset, orvepitant, is an oral NK-1 antagonist aimed at treating intense pruritus caused by targeted anti-cancer therapies. In addition to orvepitant, NeRRe's portfolio includes NT-814, a dual NK-1 and NK-3 antagonist, NT-949, a Phase I-ready NK-1 antagonist, and NT-432, a clinical candidate. The company's work targets common and chronic conditions, offering new treatment options for patients suffering from refractory or unexplained cough and other debilitating symptoms.

Mainstay Medical is a global medical device company based in Dublin, Ireland, with operations in the United States and Australia. The company focuses on developing innovative therapies for individuals suffering from chronic low back pain, a condition that affects a significant portion of the population. Mainstay Medical has created a FDA-approved restorative treatment aimed at addressing mechanical chronic low back pain. This treatment is designed to help restore muscle control and enhance functionality in the lumbar spine, ultimately improving the quality of life for patients. By collaborating with scientists and clinical experts, Mainstay Medical strives to provide effective solutions for those in need of relief from debilitating pain.

XyloCor Therapeutics, based in Newtown Square, Pennsylvania, is a biopharmaceutical company dedicated to developing gene therapies for the treatment of cardiovascular diseases, particularly advanced coronary artery disease. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, addressing critical unmet medical needs for those who have exhausted conventional treatment options. Additionally, the company is developing XC002, aimed at regenerating cardiac tissue in patients with compromised heart function due to previous heart attacks and resultant heart failure. XyloCor's innovative gene therapy technologies focus on stimulating the formation of new coronary blood vessels, thereby improving blood supply to areas of the heart that are insufficiently perfused. The company collaborates with Weill Cornell Medical College to enhance its therapeutic approaches and outcomes for patients.

Neuromod Devices Limited is a Dublin-based medical device company founded in 2010, focusing on the research and development of neuromodulation treatments for chronic tinnitus, a condition affecting approximately 10% of adults. The company has developed a patented bi-modal neuromodulation technology, exemplified by its product, the mutebutton. This device aims to promote positive therapeutic changes in the nervous system, offering a targeted approach to alleviate the suffering of patients living with chronic tinnitus. Neuromod is dedicated to providing innovative treatments that empower patients to manage their conditions while integrating seamlessly into their modern lifestyles.

Priothera Ltd is a clinical-stage company based in Dublin, Ireland, with an additional location in Saint Louis, France. It specializes in the development of orally applied sphingosine 1 phosphate (S1P) receptor modulators aimed at treating haematological malignancies. The company's primary focus is on its lead product, mocravimod, which is designed to enhance the curative potential of allogeneic haematopoietic stem cell transplants. By reducing the egress of T cell subsets from lymphatic tissues, Priothera's modulators aim to provide dual inhibition of graft versus host disease while also promoting graft versus leukemia effects, ultimately improving patient outcomes in this challenging area of medicine.

Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.

Inotrem S.A. is a biotechnology company that specializes in immunotherapy aimed at managing acute and chronic inflammatory syndromes. The company focuses on the TREM-1 pathway to regulate excessive inflammatory responses, utilizing its proprietary technology platform. Inotrem has developed a first-in-class TREM-1 inhibitor known as nangibotide (LR12), which shows promise in treating conditions such as septic shock and myocardial infarction. In addition to its acute inflammatory initiatives, Inotrem is also advancing a program targeting chronic inflammatory diseases, thereby expanding its therapeutic scope. Through its innovative approach, Inotrem aims to enhance treatment options for critical care patients facing a variety of inflammatory challenges.

Neuromod Devices Limited is a Dublin-based medical device company founded in 2010, focusing on the research and development of neuromodulation treatments for chronic tinnitus, a condition affecting approximately 10% of adults. The company has developed a patented bi-modal neuromodulation technology, exemplified by its product, the mutebutton. This device aims to promote positive therapeutic changes in the nervous system, offering a targeted approach to alleviate the suffering of patients living with chronic tinnitus. Neuromod is dedicated to providing innovative treatments that empower patients to manage their conditions while integrating seamlessly into their modern lifestyles.

Velicept Therapeutics, Inc. is a clinical development company focused on creating innovative treatments for overactive bladder (OAB) and irritable bowel syndrome (IBS). Founded in 2015 and based in Malvern, Pennsylvania, the company is advancing its lead program, solabegron, a novel compound that selectively relaxes bladder smooth muscle by stimulating beta 3-adrenoceptors. This approach aims to address unmet medical needs and improve the quality of life for patients suffering from these conditions. Velicept Therapeutics operates as a portfolio company of NeXeption, emphasizing its commitment to developing best-in-class therapeutic options.

KaNDy Therapeutics is a biotechnology company based in Stevenage, United Kingdom, focused on developing non-hormonal treatments for various menopausal symptoms, including hot flashes and nighttime awakenings. Established in 2017, the company is known for its drug NT-814, which addresses moderate to severe post-menopausal vasomotor symptoms. By providing non-hormonal therapies, KaNDy Therapeutics aims to alleviate the debilitating effects of hormone-related conditions in women. As a subsidiary of Bayer Aktiengesellschaft, the company leverages its research and development capabilities to enhance the quality of life for patients experiencing these common symptoms.

Neurent Medical Limited is a medical device company based in Galway, Ireland, founded in 2015. The company focuses on developing innovative solutions for treating rhinitis, including both allergic and non-allergic forms. It offers a single-use, minimally invasive device designed for ENT surgeons that utilizes radio-frequency technology to provide non-surgical interventions for chronic rhinitis. The device is introduced through the nostrils into the nasal cavity under direct endoscopic visualization, where it employs a microelectrode array to deliver targeted energy. This approach interrupts the autonomic function within the mucosal structures of the nasal cavities, effectively reversing the inflammatory process. By enabling treatment in an office setting, Neurent Medical aims to eliminate the complications and costs associated with traditional surgical procedures.

We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The Symani® Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients.

Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.

Mainstay Medical is a global medical device company based in Dublin, Ireland, with operations in the United States and Australia. The company focuses on developing innovative therapies for individuals suffering from chronic low back pain, a condition that affects a significant portion of the population. Mainstay Medical has created a FDA-approved restorative treatment aimed at addressing mechanical chronic low back pain. This treatment is designed to help restore muscle control and enhance functionality in the lumbar spine, ultimately improving the quality of life for patients. By collaborating with scientists and clinical experts, Mainstay Medical strives to provide effective solutions for those in need of relief from debilitating pain.

Chrono Therapeutics Inc. is a pharmaceutical company based in Hayward, California, specializing in digital transdermal drug delivery systems. Founded in 2003, the company has developed SmartStop, a digital nicotine replacement therapy that incorporates a wearable device. This innovative solution allows for programmable delivery of nicotine, adjusting timing and dosage to effectively manage withdrawal symptoms and peak addiction triggers. By combining this transdermal therapy with real-time behavioral support, Chrono Therapeutics aims to enhance smoking cessation efforts and improve clinical outcomes for users. The leadership team brings extensive experience in product development, research and development, and a deep understanding of the smoking cessation market, positioning the company to play a significant role in addressing the smoking epidemic.

Vivasure Medical Limited is a medical device company based in Galway, Ireland, specializing in the research, development, and manufacture of arterial and venous closure devices utilizing its patented PerQseal technology. The company focuses on creating polymer implants and delivery systems aimed at minimally invasive vessel closures in the fields of cardiology, interventional radiology, and vascular surgery. Its primary product is a large-bore percutaneous closure device that employs an absorbable patch to effectively close large arteriotomies following transcatheter procedures, including transcatheter aortic valve replacement and endovascular aneurysm repair. Established in 2008, Vivasure Medical is dedicated to advancing medical solutions that enhance patient outcomes in vascular access procedures.

Neuromod Devices Limited is a Dublin-based medical device company founded in 2010, focusing on the research and development of neuromodulation treatments for chronic tinnitus, a condition affecting approximately 10% of adults. The company has developed a patented bi-modal neuromodulation technology, exemplified by its product, the mutebutton. This device aims to promote positive therapeutic changes in the nervous system, offering a targeted approach to alleviate the suffering of patients living with chronic tinnitus. Neuromod is dedicated to providing innovative treatments that empower patients to manage their conditions while integrating seamlessly into their modern lifestyles.

Neuravi Limited, founded in 2009 and headquartered in Galway, Ireland, specializes in the design and development of innovative clot retrieval devices aimed at restoring blood flow in patients experiencing ischemic strokes caused by arterial blockages in the brain. The company's primary product, the EmboTrap revascularization device, is utilized in the treatment of acute ischemic strokes and is available in several European countries, including Belgium, Denmark, France, Germany, and Spain. Neuravi's focus on neuro-interventional therapies is backed by extensive research into the mechanisms of stroke, particularly regarding the capture and removal of clots, which enhances treatment efficacy and improves patient outcomes. The company collaborates with international researchers and clinicians to foster the development of new solutions for this critical medical challenge. As of April 2017, Neuravi operates as a subsidiary of DePuy Ireland Unlimited Company.

Civitas Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative pulmonary delivery therapies. Utilizing its proprietary ARCUS technology, the company creates therapeutics aimed at treating central nervous system and respiratory disorders. Civitas Therapeutics serves patients across the United States, focusing on delivering transformative treatment options to improve health outcomes.

Chrono Therapeutics Inc. is a pharmaceutical company based in Hayward, California, specializing in digital transdermal drug delivery systems. Founded in 2003, the company has developed SmartStop, a digital nicotine replacement therapy that incorporates a wearable device. This innovative solution allows for programmable delivery of nicotine, adjusting timing and dosage to effectively manage withdrawal symptoms and peak addiction triggers. By combining this transdermal therapy with real-time behavioral support, Chrono Therapeutics aims to enhance smoking cessation efforts and improve clinical outcomes for users. The leadership team brings extensive experience in product development, research and development, and a deep understanding of the smoking cessation market, positioning the company to play a significant role in addressing the smoking epidemic.

Drug development firm focused on immunology. They are headquartered in Dublin, Ireland. Opsona Therapeutics is one of Europe's most innovative and dynamic drug development companies. We are at the forefront of drug development in immunology research, with particular focus on the innate immunity pathways. Since its founding in 2004, Opsona has validated and developed a series of exciting new drug candidates and strategies which modulate the human innate immune system. We are located in Dublin, Ireland.

Trino Therapeutics is a drug discovery and early development company specializing in anti-inflammatory therapeutics. The firm is focused on creating drug candidates from a unique class of compounds based on indane dimers derived from a Taiwanese fern. Its lead candidate aims to be a first-in-class treatment for inflammatory bowel disease (IBD), targeting conditions such as ulcerative colitis and Crohn’s disease. Additionally, Trino's novel drug class exhibits broad anti-inflammatory potential, making it suitable for various applications in dermatology, pulmonary conditions, and autoimmune diseases.

Mainstay Medical is a global medical device company based in Dublin, Ireland, with operations in the United States and Australia. The company focuses on developing innovative therapies for individuals suffering from chronic low back pain, a condition that affects a significant portion of the population. Mainstay Medical has created a FDA-approved restorative treatment aimed at addressing mechanical chronic low back pain. This treatment is designed to help restore muscle control and enhance functionality in the lumbar spine, ultimately improving the quality of life for patients. By collaborating with scientists and clinical experts, Mainstay Medical strives to provide effective solutions for those in need of relief from debilitating pain.

Neuravi Limited, founded in 2009 and headquartered in Galway, Ireland, specializes in the design and development of innovative clot retrieval devices aimed at restoring blood flow in patients experiencing ischemic strokes caused by arterial blockages in the brain. The company's primary product, the EmboTrap revascularization device, is utilized in the treatment of acute ischemic strokes and is available in several European countries, including Belgium, Denmark, France, Germany, and Spain. Neuravi's focus on neuro-interventional therapies is backed by extensive research into the mechanisms of stroke, particularly regarding the capture and removal of clots, which enhances treatment efficacy and improves patient outcomes. The company collaborates with international researchers and clinicians to foster the development of new solutions for this critical medical challenge. As of April 2017, Neuravi operates as a subsidiary of DePuy Ireland Unlimited Company.

Cappella, Inc., a Dover, Del.- and Galway, Ireland-based medical device company that is developing novel solutions for the treatment of Complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease. The company was founded in 2004 by Antonio Columbo, M.D., Chief of Invasive Cardiology at San Raffaele Hospital in Milan, Italy, and Ascher Shmulewitz, M.D., Ph.D., a cardiologist, medical device entrepreneur and founder of NeoVision, Xcardia and Labcoat Ltd., and established its European headquarters in Galway in 2005.

Amarin Corporation is a clinical-stage biopharmaceutical company dedicated to enhancing the treatment of cardiovascular disease. The company is actively developing its lead candidate, AMR101, which is undergoing pivotal Phase 3 trials to assess its effectiveness in lowering triglyceride levels in patients with very high triglycerides and those with mixed dyslipidemia who are on statin therapy. Amarin leverages its expertise in lipid science and the therapeutic potential of polyunsaturated fatty acids to address cardiovascular health. The company is headquartered in Dublin, Ireland, with research and development operations based in Mystic, Connecticut, USA. Its commitment to improving cardiovascular health positions it to meet the needs of millions of patients worldwide.

Palyon Medical Corporation is a medical device company developing technologies for the treatment of chronic pain, spasticity and other neurological diseases.

Cappella, Inc., a Dover, Del.- and Galway, Ireland-based medical device company that is developing novel solutions for the treatment of Complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease. The company was founded in 2004 by Antonio Columbo, M.D., Chief of Invasive Cardiology at San Raffaele Hospital in Milan, Italy, and Ascher Shmulewitz, M.D., Ph.D., a cardiologist, medical device entrepreneur and founder of NeoVision, Xcardia and Labcoat Ltd., and established its European headquarters in Galway in 2005.

Drug development firm focused on immunology. They are headquartered in Dublin, Ireland. Opsona Therapeutics is one of Europe's most innovative and dynamic drug development companies. We are at the forefront of drug development in immunology research, with particular focus on the innate immunity pathways. Since its founding in 2004, Opsona has validated and developed a series of exciting new drug candidates and strategies which modulate the human innate immune system. We are located in Dublin, Ireland.

Vivasure Medical Limited is a medical device company based in Galway, Ireland, specializing in the research, development, and manufacture of arterial and venous closure devices utilizing its patented PerQseal technology. The company focuses on creating polymer implants and delivery systems aimed at minimally invasive vessel closures in the fields of cardiology, interventional radiology, and vascular surgery. Its primary product is a large-bore percutaneous closure device that employs an absorbable patch to effectively close large arteriotomies following transcatheter procedures, including transcatheter aortic valve replacement and endovascular aneurysm repair. Established in 2008, Vivasure Medical is dedicated to advancing medical solutions that enhance patient outcomes in vascular access procedures.